未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study基于SALIRI的 (雷替曲塞联合伊立替康) 疗法作为转移性结直肠癌患者的二线治疗 (SALLY): 一项前瞻性,多中心,非干预性,注册研究
Qin, Shuqui; Li, Jin; Zhou, Aiping; Zhang, Yanqiao; Yuan, Xianglin; Zhu, Liangjun; Qin, Baoli; Zeng, Shan; Shen, Lin; Yuan, Ying; Wang, Weibo; Liang, Jun; Zhang, Xianwen; Ye, Feng; Chen, Ping; Wang, Huaizhang; Yu, Zhenyan; Yue, Lu; Fang, Yong; Xiong, Jianping; Yang, Jianwei; Wan, Yiye; Yin, Xianli; Wang, Wenling; Xu, Nong; Wang, Xiaohong; Xiao, Zemin; Su, Huafang; Wang, Ying; Gu, Kangsheng; Tu, Shuiping; Wang, Zishu; Liu, Bo; Hu, Xiaohua; Liu, Weixian; Li, Xiaofeng
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏FCN-683, a novel second-generation BCL-2 inhibitor, is highly potent, selective and efficacious against clinically relevant venetoclax-resistant mutations
Lin, Shu (Sophie); Liu, Hongbin; Tan, Rui; Zhang, Weipeng; He, Chengxi; Rong, Yue; Huang, Zhuo; Yu, Jinhua; Wang, Yunling; Qi, Yangli; Zhao, Xingdong; Jiang, Lihua; Liu, Yanxin; Wang, Xilei; Zou, Zongyao; Sun, Jing; Gao, Yuwei; Wang, Weibo; Guan, Xiaohui; Wu, Yifang
分享
收藏
分享
收藏
分享
收藏
分享
收藏